Savara Inc. (SVRA)

We are a biopharmaceutical company developing novel, clinical-stage therapies
for serious or life-threatening diseases with significant unmet needs. Our lead
product candidate, AIR001, a sodium nitrite solution for inhalation via
nebulization, is in Phase 2 clinical development for the treatment of heart
failure with preserved ejection fraction, or HFpEF, also known as diastolic
heart failure or heart failure with preserved systolic function. Data show there
are approximately 5.7 million individuals with heart failure in the U.S. and
that approximately 50% of patients hospitalized for heart failure have
HFpEF. Enrollment is ongoing in three investigator-sponsored Phase 2 studies of
AIR001 in patients with HFpEF being conducted at prestigious research
institutions. Positive interim results from one of those studies were published
in November 2016. Additionally, positive results from a completed Phase 2 study
of AIR001 in patients with HFpEF were published in July 2016.  

Leave a Reply

Your email address will not be published. Required fields are marked *